Expression of glucocorticoid receptor spliced variants in lymphoma cell lines

✍ Scribed by Akihiro Ishida; Yasukazu Hozumi; Kaoru Goto; Tsukasa Ito; Masaru Aoyagi; Mitsunori Yamakawa

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 716 KB
• Volume: 29
• Category: Article
• ISSN: 0278-0232
• DOI: 10.1002/hon.964

✦ Synopsis

Expression of glucocorticoid receptor spliced variants in lymphoma cell lines

To the Editor Glucocorticoid (GC) has been commonly used as an anti-inflammatory reagent and a component of chemotherapeutic regimens for inducing apoptosis of haematological malignancies including leukaemia, multiple myeloma and malignant lymphoma [1]. Glucocorticoid receptor (GR) is modulated by alternative splicing of GR mRNA [2,3]. As the hormone-binding domain exists at the Cterminus, GR-a is functional and mediates the transcriptional response of GC. GR-b cannot bind to GC but inhibit GR-a-mediated transcriptional signals [4]. However, the role of GR-b in modulating GC sensitivity has been highly debated and is as yet unclear [4,5]. Although GR-P is especially highly expressed in haematological malig-nancies (23-54% of the total GR) [6], its role has not been clearly established.

Herein, for the first time, we report quantitative data of GR spliced variants in lymphoma cell lines with real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR), and documented the subcellular distribution of GR-a with GR-P in response to GC administration.

Human lymphoma cell lines Daudi, Raji, U937, HUT78 and HuT102 (a kind gift from Dr. Kudo,